Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Results from the Phase III CheckMate 77T study were published today in the New England Journal...
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms...
Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to positively impact both gut and host health...
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine and core member of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to the understanding of melanoma treatment response and resistance to cancer therapies, including groundbreaking discoveries that reveal how the...
The University of Texas MD Anderson Cancer Center today announced the launch of Texas Health Equity Alliance for Breast Cancer (THEAL), a...
Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune...
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung...
A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying...
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing...